Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Almirall raises EBITDA sharply; biologics sales drive growth
Almirall reports H1 2026 EBITDA of €150.7 million (+23.7%) and net sales of €602.7 million (+7.5%), largely meeting or exceeding expectations. The growth was driven mainly by biologics: Ebglyss reached €84.5 million in sales (+88.2%) and Ilumetri €125.2 million (+10.5%), while the dermatology business in Europe grew by 18.1%. Management confirms the full-year guidance (net sales +9–12%, EBITDA €270–290 million); net income of €39.6 million was slightly below consensus and Ebglyss’s growth slowed in Q2, which dampened the share price recovery. » More on de.investing.com
Almirall reports mixed Q1 results: net revenue slightly below forecast, EBITDA beats
Almirall reported Q1 net revenue of €291.0m (consensus €293.4m) and total revenues of €292.4m, slightly below expectations. Profitability was robust: EBITDA €67.5m (consensus €66.7m), EBIT €30.0m (consensus €29.3m), while net profit of €15.3m missed the consensus of €19.1m, weighed down by higher net financial expenses and a revaluation of an equity swap. The dermatology business grew 16.3% to €179.7m, driven by Ebglyss (€41.9m) and Ilumetri (€61.6m). Almirall confirmed its full-year outlook (net revenue €1,208–1,241m, EBITDA €270–290m) and reported a bispecific antibody candidate entering Phase I studies. » More on de.investing.com
Almirall achieves over €1.1bn revenue in 2025 for first time thanks to biologics
Almirall reports net sales of €1,108.1m for fiscal 2025 (+12.4%) and an EBITDA of €232.9m, driven by strong sales of the biologics Ilumetri and Ebglyss in Europe. Ilumetri generated €234.4m, Ebglyss grew to €110.8m, while the US business suffered from competitive pressure and negative currency effects. For 2026 management expects revenue growth of 9–12% and an EBITDA of €270–290m; medium-term, Almirall aims for a double-digit CAGR through 2030 and an EBITDA margin around 25%. The balance sheet remains solid with a net leverage of 0.0x, but the stock fell about 1.56% after the announcement. » More on de.investing.com
Almirall SA raises net sales to EUR 1.108 billion, stock falls after earnings call
Almirall SA reported for 2025 a net sales increase of 12.4% to EUR 1.108 billion and an EBITDA of EUR 233 million (+21%). Despite the record figures, the share price fell 1.56% to USD 13.22, weighed down by a weakening performance in the US market and negative currency effects. Management emphasizes the product pipeline and expects further sales growth, but sees risks from margin pressure due to higher licensing fees and intense competition. » More on de.investing.com
Almirall: no price stabilization for €250m bond
J.P. Morgan SE said that no price-stabilizing measures were taken during the stabilization period for Almirall’s recent bond issuance of €250 million. The senior, unsecured bonds have a term of 5.5 years, are callable for the first time after two years, and were issued at 100% of par. The securities are listed on the Luxembourg Stock Exchange; J.P. Morgan acted as stabilization coordinator, with BNP Paribas, BBVA, BofA Securities, CaixaBank and Santander involved as stabilization managers. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 287.98m | 10.66% |
| Gross profit | 110.63m | 21.37% |
| Net profit | 13.75m | 9.78% |
| EBITDA | 85.08m | 29.87% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.33bn |
Number of shares | 217.78m |
52-week high/low | €13.98 - €9.81 |
Dividend yield | 1.75% |
Dividends TTM | €0.19 |
Beta | 0.17 |
P/E ratio | 31.81 |
PEG ratio | 0.45 |
P/B ratio | 1.51 |
P/S ratio | 1.62 |
Company profile
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
| Name | ALMIRALL |
| CEO | Carlos Gallardo Piqué |
| Headquarters | Barcelona,
ct Spain |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 20/06/2007 |
| Employees | 2,108 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Bme | ALM.MC |
Pnk | LBTSF |
Frankfurt | E2Z.F |
Düsseldorf | E2Z.DU |
Madrid | ALM.MC |
London | 0O9B.L |
München | E2Z.MU |
Wien | ALM.VI |